# A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT07003321** · PHASE2 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** HRS-4508 tablet

## Key facts

- **NCT ID:** NCT07003321
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-12
- **Primary completion:** 2027-09
- **Final completion:** 2028-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07003321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07003321, "A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07003321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*